Invention Grant
- Patent Title: Oncolytic virus therapy for resistant tumors
-
Application No.: US14416754Application Date: 2013-03-15
-
Publication No.: US09862932B2Publication Date: 2018-01-09
- Inventor: Khalid Shah , Kaoru Tamura , Hiroaki Wakimoto
- Applicant: The General Hospital Corporation
- Applicant Address: US MA Boston
- Assignee: The General Hospital Corporation
- Current Assignee: The General Hospital Corporation
- Current Assignee Address: US MA Boston
- Agency: Nixon Peabody LLP
- Agent Mark J. FitzGerald; Srividya Subramanian
- International Application: PCT/US2013/031949 WO 20130315
- International Announcement: WO2014/018113 WO 20140130
- Main IPC: C12N7/00
- IPC: C12N7/00 ; C07K14/525 ; A61K35/763 ; A61K38/19

Abstract:
Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. One form of TRAIL contained within the oncolytic virus is a secreted form of TRAIL. Examples of various forms of oHSV and secreted TRAIL are disclosed therein. Also disclosed are host cells and therapeutic formulations comprising the recombinant oncolytic virus. Also disclosed are methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus to the subject.
Public/Granted literature
- US20150197730A1 ONCOLYTIC VIRUS THERAPY FOR RESISTANT TUMORS Public/Granted day:2015-07-16
Information query